Citi moves Myriad Genetics (Nasdaq: MYGN) from Hold/Medium Risk to Hold/High Risk and lowers price target from $21 to $18 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE